Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Janney's Ken Trbovich initiated a Buy rating on Cynapsus Therapeutics Inc (Nasdaq: CYNA) and set a price target of $24.
The company has successfully developed and marketed Apomorphine (APO) for 20 years to combat Parkinson's disease in Europe and the US. A relatively big drawback for the treatment, despite its success, is the subcutaneous injection that is necessary. Cynapsus is developing a sublingual APO that will eliminate this injection. Trobovich sees a high rate of clinical and commercial success for the new treatment.
The OFF condition, which APO alleviates, is a problem for every patient afflicted with this disease. APO has been successful in battling the disease and has produced numerous positive outcomes for patients over the years, but the treatments subcutaneous injection has limited its use.
"It is rarely used in the U.S. and sales in Europe last year were just $63 million," Trobovich stated.
Cynapsus plans to report Phase 3 trial results for its new sublingual APO in late Q2 or early Q3.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!